J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC

Johnson & Johnson (JNJ) announced that the FDA approved a combination therapy involving EFGR/MET inhibitor Rybrevant (amivantamab) for expanded use in certain patients with non-small cell lung cancer (NSCLC).With this nod, Rybrevant combined with standard-of-care chemotherapy (carboplatin and pemetrexed) is approved for treating patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions (ex19del) or L858R substitution mutations, whose disease has progressed on or after receiving with an ...